Article Information
History
- October 5, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Sonia Pérez-Rodríguez1,δ,
- Meiby de la Caridad Rodríguez-González2,δ,
- Rolando Ochoa-Azze2,δ,#,
- Yanet Climent-Ruiz2,
- Carlos Alberto González-Delgado1,
- Beatriz Paredes-Moreno2,
- Carmen Valenzuela-Silva3,
- Laura Rodríguez-Noda2,
- Rocmira Perez-Nicado2,
- Raúl González-Mugica2,
- Marisel Martínez-Pérez2,
- Belinda Sánchez-Ramírez4,
- Tays Hernández-García4,
- Alina Díaz-Machado1,
- Maura Tamayo-Rodríguez1,
- Alis Martín-Trujillo1,
- Jorman Rubino-Moreno1,
- Anamary Suárez-Batista5,
- Marta Dubed-Echevarría5,
- María Teresa Pérez-Guevara5,
- Mayté Amoroto-Roig6,
- Yanet Chappi-Estévez6,
- Gretchen Bergado-Báez4,
- Franciscary Pi-Estopiñán4,
- Guang-Wu Chen7,
- Yuri Valdés-Balbín1,
- Dagmar García-Rivera1 and
- Vicente Vérez-Bencomo1
- 1National Centre of Toxicology (CENATOX), Havana, Cuba
- 2Finlay Vaccine Institute, Havana, Cuba
- 3Institute of Cybernetics, Mathematics and Physics, Havana, Cuba
- 4Centre of Molecular Immunology, Havana, Cuba
- 5Research Center of Civil Defense, Havana, Cuba
- 6National Coordinating Centre of Clinical Trials
- 7Chengdu Olisynn Biotech. Co. Ltd., and State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, People’s Republic of China
- ↵#Corresponding author:
Rolando Ochoa-Azze, MD, PhD. Finlay Vaccine Institute. 21st Ave. Nº 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba. Tel: (53) 72719131, Email address: ochoa{at}finlay.edu.cu
Posted October 05, 2021.
A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: safety, reactogenicity and immunogenicity
